Hypoxic Exercise and Glucose Metabolism
Ключови думи
Резюме
Описание
In the present randomized, single-blind, placebo-controlled cross-over study, subjects will be exposed to normobaric 1) mild hypoxia (oxygen level: 15%) and 2) normoxia (oxygen level: 21%) during exercise (2 x 30min/day on a cycle ergometer) of the same relative exercise intensity (equal to 50%WMAX under normoxic conditions) for 4 consecutive days. Subjects will be randomly assigned to each condition (computer-generated randomization plan; block size, n=4), separated by a washout period (3-6 weeks). To accomplish this, subjects will exercise in an oxygen chamber in which oxygen concentration of the ambient air and, as such, oxygen levels can be tightly controlled and monitored. Subjects will cycle two times a day for 30 minutes at 50% WMAX, determined by an incremental workload test. Since we will allow 5-10 min for subjects to get ready to start the 30-min exercise session, and take into account a 5-min cooling down period before leaving the hypoxic room again, subjects will be in the room for 45 min for each session.
After initial screening, subjects are asked to visit the university for two periods of 5 consecutive days each with a washout period of 3-6 weeks. During the first 4 days (time investment: 4.5 hours/day), subjects will be undergoing the exercise regimen, as described above.
- At day 1, on the first morning of each regimen, a glucose sensor (Enlite Glucose Sensor MiniMed; Medtronic). The sensor will be inserted subcutaneously, will be inserted subcutaneously, at 5 cm from the umbilicus, on the right side of the abdomen, and will be connected to a continuous glucose monitor (iPro2 Professional CGM MiniMed; Medtronic, Northridge, CA, USA). The sensor will remain inserted throughout the study (days 1-5). Furthermore, a physical activity monitor (ActivPAL3 micro monitor) will be applied at the same moment, to monitor physical activity of participants. At the end of day 5, the glucose sensor, and the physical activity monitor will be removed.
- At days 1-5 (time investment: 4.5 hours), fasting blood samples will be collected to determine plasma metabolites and inflammatory markers, and blood pressure and body weight will be monitored.
- At day 5 (time investment: 8 hours), a mixed liquid meal challenge will be performed to determine fasting and postprandial metabolite concentrations, and substrate oxidation (using indirect calorimetry). A skeletal muscle biopsy (m. vastus lateralis) will be collected under fasting conditions. Moreover, HOMA-IR will be used to estimate insulin resistance, using fasting plasma glucose and insulin values measured on the day after completion of the 4 day regimen.
After initial screening, the assessment of basal metabolic rate (BMR) and the incremental workload test (to determine the maximal workload, WMAX), subjects will have to invest approximately 52 hours.
Дати
| Последна проверка: | 01/31/2020 |
| Първо изпратено: | 07/15/2019 |
| Очаквано записване подадено: | 02/19/2020 |
| Първо публикувано: | 02/20/2020 |
| Изпратена последна актуализация: | 02/19/2020 |
| Последна актуализация публикувана: | 02/20/2020 |
| Действителна начална дата на проучването: | 07/21/2019 |
| Приблизителна дата на първично завършване: | 06/30/2020 |
| Очаквана дата на завършване на проучването: | 07/31/2020 |
Състояние или заболяване
Интервенция / лечение
Other: Moderate intensity exercise under mild normobaric hypoxia and normoxia
Фаза
Групи за ръце
| Arm | Интервенция / лечение |
|---|---|
| Experimental: Moderate intensity exercise under mild normobaric hypoxia The participants will perform moderate intensity exercise at heart rate corresponding with 50%WMAX (determined during maximal workload test) under mild normobaric hypoxia (FiO2: 15%), two times 30 minutes per day for 4 consecutive days on a cycle ergometer. 24h glucose concentration will be monitored continuously. Afterwards, a meal test challenge will be performed at day 5 to determine fasting/postprandial substrate oxidation. | |
| Placebo Comparator: Moderate intensity exercise under normoxia The participants will perform moderate intensity exercise at 50% WMAX (determined during maximal workload test) under normoxia (FiO2: 21%) two times 30 minutes per day for 4 consecutive days on a cycle ergometer. 24h glucose concentration will be monitored continuously. Afterwards, a meal test challenge test will be performed at day 5 to determine fasting/postprandial substrate oxidation. |
Критерии за допустимост
| Възрасти, отговарящи на условията за проучване | 30 Years Да се 30 Years |
| Полове, допустими за проучване | Male |
| Приема здрави доброволци | Да |
| Критерии | Inclusion Criteria: - overweight or obese (BMI >28 kg/m2) - impaired glucose tolerance (2h glucose: >7.8 - 11.1 mmol/L) - subjects have to be weight-stable for at least 3 months prior to participation (no change in bodyweight: <3kg change) Exclusion Criteria: - cardiovascular disease (determined by questionnaire, blood pressure (Subjects with moderate to severe hypertension (grade 2 or 3 based on WHO criteria) - type 2 diabetes mellitus - cancer - asthma - bronchitis - chronic obstructive pulmonary disease - lung fibrosis - obstructive sleep apnea - use of oxygen at home situation - resting SpO2 ≤93% - abnormal pre-bronchodilator forced expiratory volume (FEV1) and forced vital capacity (FVC) - liver or kidney malfunction (determined based on ALAT and creatinine levels, respectively) - disease with a life expectancy shorter then 5 years - lactose intolerance - abuse of products (alcohol consumption > 15 units/week) - smoking - plans to lose weight (subjects will be asked if they have weight loss plans (e.g. to increase their physical activity level or change diet) - use of high doses of anti-oxidant vitamins - use of any medication that influences glucose metabolism and inflammation - shift working |
Резултат
Първични изходни мерки
1. Average 24 hour glucose concentration (at day 4) [Change of average glucose concentration compared to moderate intensity exercise under normoxia (21% oxygen) at day 4]
Вторични изходни мерки
1. Glycemic variability over 24 hours [Change of glycemic variability over 24 hours compared to moderate intensity exercise under normoxia (21% oxygen) at day 2, 3, 4 and 5]
2. Time in hyper/hypoglycaemia [Change of time spent in hyper/hypoglycemia compared to moderate intensity exercise under normoxia (21% oxygen) at day 2, 3, 4 and 5]
3. Energy expenditure [Change of energy expenditure compared to moderate intensity exercise under normoxia (21% oxygen) at day 5 during the meal-test]
4. Substrate oxidation [Change of substrate oxidation compared to moderate intensity exercise under normoxia (21% oxygen) at day 5 during the meal-test]
5. Systolic and diastolic blood pressure [Change of systolic and diastolic blood pressure compared to moderate intensity exercise under normoxia (21% oxygen) at day 1, 2, 3, 4 and 5 under fasting conditions.]
6. HOMA-IR [Change of HOMA-IR compared to moderate intensity exercise under normoxia (21% oxygen) at day 5 under fasting conditions]
7. Gene/protein expression of AMPK and phosphorylation of AMPK in skeletal muscle tissue [Change of gene/protein expression of AMPK in skeletal muscle tissue compared to moderate intensity exercise under normoxia (21% oxygen) at day 5, under fasting conditions, when skeletal muscle biopsy will be collected]
8. Systemic concentration of interleukin-8 (IL-8; inflammatory marker) [Change of concentrations of IL-8 compared to moderate intensity exercise under normoxia (21% oxygen) during fasting conditions at day 5]
9. Systemic concentration of tumor necrosis factor alpha (TNF-alpha; inflammatory marker) [Change of concentrations of TNF-alpha compared to moderate intensity exercise under normoxia (21% oxygen) during fasting conditions at day 5]
10. Systemic concentration of interferon-gamma (IFN-gamma; inflammatory marker) [Change of concentrations of IFN-gamma compared to moderate intensity exercise under normoxia (21% O2) during fasting conditions at day 5]
11. Systemic concentration of interleukin-6 (IL-6; inflammatory marker) [Change of concentrations of IL-6 compared to moderate intensity exercise under normoxia (21% oxygen) during fasting conditions at day 5]
12. Fasting and postprandial plasma glucose concentration [Change of fasting and postprandial plasma glucose concentrations (mmol/L) compared to moderate intensity exercise under normoxia (21% oxygen) at day 5]
13. Fasting and postprandial plasma insulin concentration [Change of fasting and postprandial plasma insulin concentrations (mU/L) compared to moderate intensity exercise under normoxia (21% oxygen) at day 5]
14. Fasting and postprandial plasma free fatty acids concentration [Change of fasting and postprandial plasma free fatty acids concentrations (μmol/L) compared to moderate intensity exercise under normoxia (21% oxygen) at day 5]
15. Fasting and postprandial plasma glycerol concentration [Change of fasting and postprandial plasma glycerol concentrations (μmol/L) compared to moderate intensity exercise under normoxia (21% oxygen) at day 5]
16. Fasting and postprandial plasma triglycerides concentration [Change of fasting and postprandial plasma triglycerides concentrations (μmol/L) compared to moderate intensity exercise under normoxia (21% oxygen) at day 5]
17. Fasting and postprandial plasma lactate concentration [Change of fasting and postprandial plasma lactate concentrations (mmol/L) compared to moderate intensity exercise under normoxia (21% oxygen) at day 5]
